Protara Therapeutics’ TARA-002 shows early activity in NMIBC, says TD Cowen

TD Cowen made no change to the firm’s Outperform rating or $50 price target on Protara Therapeutics. The firm is "encouraged" after Protara disclosed positive safety for TARA-002’s Phase 1a trial in high-grade non-muscle invasive bladder cancer, with very early signs of activity, the analyst tells investors in a research note. TD Cowen believes the most significant opportunity for TARA-002 is in NMIBC, with a high unmet need.